Last reviewed · How we verify
NCT05316727: ENDALI
Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury
trial in Acute Lung Injury in 101 participants. Completed in 1 December 2024.
1 December 2024
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 101 |
| Start date | 15 November 2021 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across United States |
Conditions studied
- Acute Lung Injury — all drugs for Acute Lung Injury →
- Pulmonary Injury — all drugs for Pulmonary Injury →
- Electronic Cigarette Use — all drugs for Electronic Cigarette Use →
- Electronic Cigarette Related Lung Injury — all drugs for Electronic Cigarette Related Lung Injury →
Sponsor
University of Pittsburgh
Who can join
Adults 18 to 80, any sex, with Acute Lung Injury or Pulmonary Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05316727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lung Injury
Currently open trials in the same condition.
- NCT05704166 — PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients · Phase 2 · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05316727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05316727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing